References
- Tanner M, de Savigny D. Malaria eradication back on the table. Bull. World Health Organ.86, 82 (2008).
- Barnes KI, Durrheim DN, Little F et al. Effect of artemether–lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med.2, e330 (2005).
- Bhattarai A, Ali AS, Kachur SP et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med.4, e309 (2007).
- Graves PM, Osgood DE, Thomson MC et al. Effectiveness of malaria control during changing climate conditions in Eritrea, 1998–2003. Trop. Med. Int. Health13, 218–228 (2008).
- Okiro EA, Hay SI, Gikandi PW et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar. J.6, 151 (2007).
- D’Acremont V, Landry P, Mueller I, Pecoud A, Genton B. Clinical and laboratory predictors of imported malaria in an outpatient setting, an aid to medical decision making in returning travelers with fever. Am. J. Trop. Med. Hyg.66, 481–486 (2002).
- Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci.266, 169–177 (1973).
- Pombo DJ, Lawrence G, Hirunpetcharat C et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet360, 610–617 (2002).
- Genton B, Betuela I, Felger I et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1–2b trial in Papua New Guinea. J. Infect. Dis.185, 820–827 (2002).
- Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children, randomised controlled trial. Lancet364, 1411–1420 (2004).
- Leder K, Black J, O’Brien D et al. Malaria in travelers, a review of the GeoSentinel surveillance network. Clin. Infect. Dis.39, 1104–1112 (2004).
- Steffen R, Heusser R, Machler R et al. Malaria chemoprophylaxis among European tourists in tropical Africa, use, adverse reactions, and efficacy. Bull. World Health Organ.68, 313–322 (1990).
- Phillips-Howard PA, Radalowicz A, Mitchell J, Bradley DJ. Risk of malaria in British residents returning from malarious areas. BMJ300, 499–503 (1990).
- Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K. Malaria risk in travellers. Emerg. Infect. Dis.11, 436–441 (2005).
- Behrens RH, Bisoffi Z, Bjorkman A et al. Malaria prophylaxis policy for travellers from Europe to the Indian subcontinent. Malar. J.5, 7 (2006).
- Behrens RH, Carroll B, Beran J et al. The low and declining risk of malaria in travelers to Latin America, is there still an indication for chemoprophylaxis? Malar. J.6, 114 (2007).
- Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA296, 2234–2244 (2006).
- Lengeler C. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst. Rev. (2), CD000363 (2004).
- Gardner MJ, Hall N, Fung E et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature419, 498–511 (2002).
- Mu J, Awadalla P, Duan J et al. Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat. Genet.39, 126–130 (2007).
- Kanoi BN, Egwang TG. New concepts in vaccine development in malaria. Curr. Opin. Infect. Dis.20, 311–316 (2007).
- Sundaresh S, Doolan DL, Hirst S et al. Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics22, 1760–1766 (2006).
- Davies DH, Liang X, Hernandez JE et al. Profiling the humoral immune response to infection by using proteome microarrays, high-throughput vaccine and diagnostic antigen discovery. Proc. Natl Acad. Sci. USA102, 547–552 (2005).
- Corradin G, Villard V, Kajava AV. Protein structure based strategies for antigen discovery and vaccine development against malaria and other pathogens. Endocr. Metab. Immune Disord. Drug Targets7(4), 259–265 (2007).
- Kidgell C, Volkman SK, Daily J et al. A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog.2, e57 (2006).
- Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, Anders RF. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect. Immun.71, 1416–1426 (2003).
- Kennedy MC, Wang J, Zhang Y et al.in vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1), production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun.70, 6948–6960 (2002).
- Felger I, Genton B, Smith T, Tanner M, Beck HP. Molecular monitoring in malaria vaccine trials. Trends Parasitol.19, 60–63 (2003).
- Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development, malaria. Vaccine25, 1567–1580 (2007).
- Hu YC, Yao K, Wu TY. Baculovirus as an expression and/or delivery vehicle for vaccine antigens. Expert Rev. Vaccines7(3), 363–371 (2008).
- Wu Y, Przysiecki C, Flanagan E et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl Acad. Sci. USA103, 18243–18248 (2006).
- Corradin G. Peptide based malaria vaccine development, personal considerations. Microbes Infect.9, 767–771 (2007).
- Mueller MS, Renard A, Boato F et al. Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect. Immun.71, 4749–4758 (2003).
- Bentley GA. Functional and immunological insights from the three-dimensional structures of Plasmodium surface proteins. Curr. Opin. Microbiol.9, 395–400 (2006).
- Todryk SM, Hill AV. Malaria vaccines, the stage we are at. Nat. Rev. Microbiol.5, 487–489 (2007).
- Westerfeld N, Pluschke G, Zurbriggen R. Optimized malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wien. Klin. Wochenschr.118, 50–57 (2006).
- Hirunpetcharat C, Wipasa J, Sakkhachornphop S et al. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine21, 2923–2932 (2003).
- Jeamwattanalert P, Mahakunkijcharoen Y, Kittigul L, Mahannop P, Pichyangkul S, Hirunpetcharat C. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clin. Vaccine Immunol.14, 342–347 (2007).
- Mullen GE, Giersing BK, Jose-Popoola O et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine24, 2497–2505 (2006).
- Vekemans J, Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines7(2), 223–240 (2008).
- Graves P, Gelband H. Vaccines for preventing malaria (SPf66). Cochrane Database Syst. Rev. (4), CD005966 (2006).
- Druilhe P, Barnwell JW. Pre-erythrocytic stage malaria vaccines, time for a change in path. Curr. Opin. Microbiol.10, 371–378 (2007).
- Graves P, Gelband H. Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database Syst. Rev. (4), CD006198 (2006).
- Heppner DG Jr, Kester KE, Ockenhouse CF et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria, progress at the Walter Reed Army Institute of Research. Vaccine23, 2243–2250 (2005).
- Bojang KA. RTS,S/AS02A for malaria. Expert Rev. Vaccines5(5), 611–615 (2006).
- Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med.336, 86–91 (1997).
- Kester KE, McKinney DA, Tornieporth N et al. A Phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine25, 5359–5366 (2007).
- Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia, a randomised trial. Lancet358, 1927–1934 (2001).
- Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children, single-blind extended follow-up of a randomised controlled trial. Lancet366, 2012–2018 (2005).
- Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique, a double blind randomised controlled Phase I/IIb trial. Lancet370, 1543–1551 (2007).
- Wipasa J, Riley EM. The immunological challenges of malaria vaccine development. Expert Opin. Biol. Ther.7, 1841–1852 (2007).
- Blum-Tirouvanziam U, Beghdadi-Rais C, Roggero MA et al. Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides. J. Immunol.153, 4134–4141 (1994).
- Roggero MA, Filippi B, Church P et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol. Immunol.32, 1301–1309 (1995).
- Lopez JA, Gonzalez JM, Kettner A et al. Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum, recognition by human T-cells and immunogenicity in owl monkeys. Ann. Trop. Med. Parasitol.91, 253–265 (1997).
- Meraldi V, Audran R, Romero JF et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242–310 from the circumsporozoite protein of Plasmodium berghei. Vaccine21, 2485–2491 (2003).
- Lopez JA, Roggero MA, Duombo O et al. Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors. Am. J. Trop. Med. Hyg.55, 424–429 (1996).
- Lopez JA, Weilenman C, Audran R et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur. J. Immunol.31, 1989–1998 (2001).
- Genton B, D’Acremont V, Lurati F et al. Randomized, double-blind placebo-controlled Phase IIa trial to test efficacy of the malaria vaccine PfCS102 to protect non-immune volunteers against falciparum challenge. Presented at: Proceedings of The Multilateral Initiative on Malaria Meeting. Yaounde, Cameroon, 14–17 November 2005.
- Moorthy VS, Imoukhuede EB, Milligan P et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med.1, e33 (2004).
- Bejon P, Mwacharo J, Kai O et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP, MVA ME-TRAP among children in Kenya. PLoS Clin. Trials1, e29 (2006).
- Gruner AC, Snounou G, Brahimi K, Letourneur F, Renia L, Druilhe P. Pre-erythrocytic antigens of Plasmodium falciparum, from rags to riches? Trends Parasitol.19, 74–78 (2003).
- Hillier CJ, Ware LA, Barbosa A et al. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect. Immun.73, 2109–2115 (2005).
- Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL. Malaria vaccines, are we getting closer? Curr. Opin. Mol. Ther.9, 12–24 (2007).
- Daubersies P, Thomas AW, Millet P et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat. Med.6, 1258–1263 (2000).
- Perlaza BL, Zapata C, Valencia AZ et al. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur. J. Immunol.33, 1321–1327 (2003).
- Reed ZH, Friede M, Kieny MP. Malaria vaccine development, progress and challenges. Curr. Mol. Med.6, 231–245 (2006).
- Graves P, Gelband H. Vaccines for preventing malaria (blood-stage). Cochrane Database Syst. Rev. (4), CD006199 (2006).
- Lawrence G, Cheng QQ, Reed C et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine18, 1925–1931 (2000).
- Ockenhouse CF, Angov E, Kester KE et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine24, 3009–3017 (2006).
- Stoute JA, Gombe J, Withers MR et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine25, 176–184 (2007).
- Thera MA, Doumbo OK, Coulibaly D et al. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults, results of a Phase I randomized trial. PLoS Clin. Trials1, e34 (2006).
- Withers MR, McKinney D, Ogutu BR et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate, a randomized Phase Ib dose-escalation trial in Kenyan children. PLoS Clin. Trials1, e32 (2006).
- Malkin E, Long CA, Stowers AW et al. Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clin. Trials2, e12 (2007).
- Druilhe P, Spertini F, Soesoe D et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med.2, e344 (2005).
- Malkin EM, Diemert DJ, McArthur JH et al. Phase 1 clinical trial of apical membrane antigen 1, an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun.73, 3677–3685 (2005).
- Dicko A, Diemert DJ, Sagara I et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS ONE2, e1045 (2007).
- Polhemus ME, Magill AJ, Cummings JF et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine25, 4203–4212 (2007).
- Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults, results of a Phase 1 randomized controlled trial. PLoS ONE3, e1465 (2008).
- Theisen M, Dodoo D, Toure-Balde A et al. Selection of glutamate-rich protein long synthetic peptides for vaccine development, antigenicity and relationship with clinical protection and immunogenicity. Infect. Immun.69, 5223–5229 (2001).
- Hermsen CC, Verhage DF, Telgt DS et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a Phase 1 malaria vaccine trial. Vaccine25, 2930–2940 (2007).
- Li J, Matsuoka H, Mitamura T, Horii T. Characterization of proteases involved in the processing of Plasmodium falciparum serine repeat antigen (SERA). Mol. Biochem. Parasitol.120, 177–186 (2002).
- Peek LJ, Brandau DT, Jones LS, Joshi SB, Middaugh CR. A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine. Vaccine24, 5839–5851 (2006).
- Pattnaik P, Shakri AR, Singh S, Goel S, Mukherjee P, Chitnis CE. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine25, 806–813 (2007).
- Arévalo-Herrera M, Castellanos A, Yazdani SS et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am. J. Trop. Med. Hyg.73, 25–31 (2005).
- Makobongo MO, Keegan B, Long CA, Miller LH. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 a protects against severe disease during Plasmodium falciparum reinfection. J. Infect. Dis.193, 731–740 (2006).
- Matuschewski K. Vaccine development against malaria. Curr. Opin. Immunol.18, 449–457 (2006).
- Fried M, Wendler JP, Mutabingwa TK, Duffy PE. Mass spectrometric analysis of Plasmodium falciparum erythrocyte membrane protein-1 variants expressed by placental malaria parasites. Proteomics4, 1086–1093 (2004).
- Salanti A, Staalsoe T, Lavstsen T et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol. Microbiol.49, 179–191 (2003).
- Salanti A, Dahlback M, Turner L et al. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J. Exp. Med.200, 1197–1203 (2004).
- Avril M, Gamain B, Lepolard C, Viaud N, Scherf A, Gysin J. Characterization of anti-var2CSA–PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies. Microbes Infect.8, 2863–2871 (2006).
- Dahlback M, Rask TS, Andersen PH et al. Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog.2, e124 (2006).
- Pan W, Huang D, Zhang Q et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J. Immunol.172, 6167–6174 (2004).
- Hu J, Chen Z, Gu J et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in Montanide ISA 720 in healthy adults. PLoS ONE3, e1952 (2008).
- Malkin EM, Durbin AP, Diemert DJ et al. Phase 1 vaccine trial of Pvs25H, a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine23, 3131–3138 (2005).
- Saul A. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Parasitology1–10 (2008).
- Genton B, Pluschke G, Degen L et al. A randomized placebo-controlled Phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE2, e1018 (2007).
- Okitsu SL, Silvie O, Westerfeld N et al. A virosomally formulated malaria peptide vaccine elicits a long-lasting Plasmodium falciparum sporozoite-inhibitory antibody response in human volunteers. PLoS Clin. Trials2(12), e1278 (2007).
- Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase IIa clinical trial. PLoS ONE3, e1493 (2008).
- Matuschewski K, Mueller AK. Vaccines against malaria – an update. FEBS J.274, 4680–4687 (2007).
- Luke TC, Hoffman SL, Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol.206, 3803–3808 (2003).
- Jobe O, Lumsden J, Mueller AK et al. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-γ-producing CD8+ T cells. J. Infect. Dis.196, 599–607 (2007).
- Hoffman SL, Goh LM, Luke TC et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis.185, 1155–1164 (2002).
- Committee on US Military Vaccine Research. Battling Malaria, Strengthening the US Military Malaria Vaccine Program. (2006).
- Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA296, 2234–2244 (2006).
- Landry P, Iorillo D, Darioli R, Burnier M, Genton B. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic pillbox. J. Travel Med.13, 8–14 (2006).
- Fraser A, Goldberg E, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst. Rev. (3), CD001261 (2007).
- Barat LM. Four malaria success stories, how malaria burden was successfully reduced in Brazil, Eritrea, India, and Vietnam. Am. J. Trop. Med. Hyg.74, 12–16 (2006).
- Moorthy V, Reed Z, Smith PG. Measurement of malaria vaccine efficacy in Phase III trials, report of a WHO consultation. Vaccine25, 5115–5123 (2007).
- Maire N, Tediosi F, Ross A, Smith T. Predictions of the epidemiologic impact of introducing a pre-erythrocytic vaccine into the expanded program on immunization in sub-Saharan Africa. Am. J. Trop. Med. Hyg.75, 111–118 (2006).
- Bergmann-Leitner ES, Duncan EH, Mullen GE et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am. J. Trop. Med. Hyg.75, 437–442 (2006).
- Müller I, Reed Z, Genton B. Guidelines for the clinical evaluation of Plasmodium vivax vaccines. WHO/IVR Document (2007).
- WHO. Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infection. Document TDR/MAL/VAC/97 (1997).
- Moorthy VS, Reed Z, Smith PG; WHO Group on Measures of Malaria Vaccine Efficacy. Measurement of malaria vaccine efficacy in Phase III trials, report of a WHO consultation. Vaccine25(28), 5115–5123 (2007).
Websites
- WHO. International Clinical Trials Registry Platform (ICTRP) www.who.int/ictrp/search/en/index.html (Accessed 27 March 2008)
- Clinicaltrials.gov. A service of the US National Institutes of Health www.clinicaltrials.gov (Accessed 27 March 2008)
- Malaria Vaccine Technology Roadmap www.malariavaccineroadmap.net (Accessed 27 March 2008)
- WHO. Portfolio of candidate malaria vaccines currently in development March 2005 www.who.int/vaccine_research/documents/en/malaria_table.pdf (Accessed 27 March 2008)